Travere Therapeutics Q3 2024 GAAP EPS $(0.70), Inline, Sales $62.90M Beat $59.70M Estimate

TRAVERE THERAPEUTICS INC -0.48% Post

TRAVERE THERAPEUTICS INC

TVTX

18.47

18.47

-0.48%

0.00% Post

Travere Therapeutics (NASDAQ: TVTX) reported quarterly losses of $(0.70) per share which met the analyst consensus estimate. The company reported quarterly sales of $62.90 million which beat the analyst consensus estimate of $59.70 million by 5.35 percent. This is a 69.56 percent increase over sales of $37.09 million the same period last year.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via